搜索筛选:
搜索耗时2.8582秒,为你在为你在102,285,761篇论文里面共找到 5 篇相符的论文内容
类      型:
[会议论文] 作者:Ming Duan,Tang-Lin Zhang,Wei Hu,Song-Guang Xie,Zhong-Jie Li,Zuo-Yan Zhu, 来源:The 2nd International Congress on Biological Invasions, ICBI 年份:2013
[会议论文] 作者:Li-Liang Wei,Zhi-Fen Pan,Xiao-Mei Yu,Ting-Ting Jiang,Chang-Ming Liu,Ze-Peng Ping,Zhong-Liang Chen,Zhong-Jie Li, 来源:2015中国转化医学大会暨中国转化医学联盟成立大会 年份:2015
There was lack of a rapid and efficient determination method for cured pulmonary tuberculosis (TB).iTRAQ labeling coupled with 2D LC-MS/MS analysis was used to identify the differentially expressed se...
[期刊论文] 作者:Zhong-jie Li,Hui-qi Dai,Xiao-wei Huang,Ji Feng,Jing-huan Deng,Zi-xuan Wang,Xiao-mei Yang,Yu-jia Liu,Yong, 来源:中国药理学报(英文版) 年份:2021
Sorafenib is the first-line medication for advanced hepatocellular carcinoma(HCC),but it can only extend limited survival.It is imperative to find a combination...
[会议论文] 作者:Xiao-Mei Yu,Chang-Ming Liu,Xue-Hong Liu,Xian-Min Feng,Ze-Peng Ping,Ting-Ting Jiang,Zhong-Liang Chen,Zhong-Jie Li, 来源:2015中国转化医学大会暨中国转化医学联盟成立大会 年份:2015
Ficolin-2 (FCN2) is an innate immune pattern recognition molecule that can activate the complement pathway, opsonophagocytosis, and elimination of the pathogens.The present study aimed to investigate...
[期刊论文] 作者:Feng,Pei-zhi Lu,Guang-zhi Zhu,Shing Chung Hooi,Yong Wu,Xiao-wei Huang,Hui-qi Dai,Pan-hong Chen,Zhong-jie Li, 来源:中国药理学报(英文版) 年份:2021
Sorafenib is the first-line treatment of advanced hepatocellular carcinoma(HCC).However,there is a lack of validated biomarkers to predict sorafenib sensitivity...
相关搜索: